Novartis to Squeeze Out MorphoSys Minority Shareholders, Initiate Delisting
Novartis to Squeeze Out MorphoSys Minority Shareholders, Initiate Delisting
诺华将强制收购morphosys的少数股东，并开始退市
MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as "Novartis") also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys' minority shareholders.
MorphoSys AG（FSE：MOR，纳斯达克股票代码：MOR）今天宣布，继诺华于2024年5月成功完成对MorphoSys的收购后，该公司已与诺华BidCo AG和诺华股份公司签订了退市协议。诺华BidCo德国股份公司（以及诺华BidCo AG和诺华股份公司以下统称为 “诺华”）还告知MorphoSys，他们打算通过启动对MorphoSys少数股东的挤出来将MorphoSys并入诺华。
In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys shareholders € 68.00 per share in cash...
2024年4月，诺华提交了对所有已发行的Morph...
登录免费看全文
登录/注册